|1.||Berman, Brian: 7 articles (12/2015 - 01/2012)|
|2.||Ogbourne, Steven M: 7 articles (10/2014 - 03/2007)|
|3.||Goldenberg, Gary: 5 articles (01/2015 - 02/2011)|
|4.||Katsamas, Janelle: 5 articles (12/2014 - 02/2009)|
|5.||Tyring, Stephen K: 5 articles (06/2014 - 03/2012)|
|6.||Larsson, Thomas: 4 articles (05/2015 - 06/2013)|
|7.||Welburn, Peter: 4 articles (12/2014 - 02/2009)|
|8.||Swanson, Neil: 4 articles (06/2014 - 03/2012)|
|9.||Suhrbier, Andreas: 4 articles (01/2013 - 09/2006)|
|10.||Lord, Janet M: 4 articles (10/2012 - 08/2005)|
01/01/2012 - "In human studies, ingenol mebutate achieved high clearance of actinic keratosis on the head and body after 2-3 consecutive daily treatments when measured by complete or partial clearance of lesions. "
06/01/2013 - "To assess 12-month recurrence rates and safety associated with ingenol mebutate gel treatment in patients who previously had achieved complete clearance of actinic keratoses. "
05/01/2015 - "High-quality evidence suggests that ingenol mebutate may be effective in treating actinic keratosis. "
12/24/2012 - "Treatment with ingenol mebutate gel was generally associated with sustained clearance of actinic keratoses in the longer term. "
06/01/2009 - "Short-course, field-directed therapy with ingenol mebutate gel for actinic keratoses on non-facial sites seems to be effective with a favorable safety profile and potential benefits over topical agents that require a more prolonged course of treatment."
|2.||Basal Cell Carcinoma (Rodent Ulcer)
11/01/2014 - "Superficial basal cell carcinoma successfully treated with ingenol mebutate gel 0.05%."
05/01/2010 - "Two applications of ingenol mebutate gel, 0.05%, are safe and have efficacy in patients with superficial basal cell carcinoma."
05/01/2010 - "A total of 60 patients with histologically confirmed superficial basal cell carcinoma (lesion size, 4-15 mm) were randomized to treatment on days 1 and 2 (Arm A) or days 1 and 8 (Arm B) and, within each arm, to ingenol mebutate gel, 0.0025%, 0.01% or 0.05%, or vehicle gel. "
02/01/2012 - "Several studies have reported on the safety and efficacy of topical ingenol mebutate gel, a derivative of the plant Euphorbia peplus, in the treatment of actinic keratosis and superficial basal cell carcinoma. "
09/01/2014 - "A scarring reaction to the treatment of basal cell carcinoma with ingenol mebutate."
|3.||Skin Neoplasms (Skin Cancer)
05/01/2013 - "Premarketing trials for treatment of nonmelanoma skin cancers also showed promising results for ingenol mebutate. "
05/01/2013 - "Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers."
08/01/2015 - "Topically applied ingenol mebutate (IngMeb) is approved for field-treatment of actinic keratosis and is currently being investigated for treatment of non-melanoma skin cancer (NMSC). "
01/01/2014 - "Synthesis, biological evaluation and SAR of 3-benzoates of ingenol for treatment of actinic keratosis and non-melanoma skin cancer."
10/15/2013 - "Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer."
|4.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/01/2013 - "Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice."
01/01/2013 - "Herein, we describe the efficacy of ingenol mebutate for the topical treatment of squamous cell carcinoma (SCC) using a wild-type mouse model (SKH1) and the UV-induced mouse SCC cell line, T7. "
12/01/2014 - "Ingenol mebutate should be considered a highly relevant field therapy for AK and the prevention of progression to squamous cell carcinoma."
12/01/2015 - "Rapidly-growing squamous cell carcinoma shortly after treatment with ingenol mebutate for actinic keratoses: report of two cases."
10/01/2012 - "We investigated the proposed necrotic mechanism of ingenol mebutate, a natural compound with anti-cancer properties in human keratinocytes, the human squamous cell carcinoma cell line HSC-5, and HeLa cervix carcinoma cells. "
09/01/2011 - "The efficacy of ingenol to inhibit HIV-1 infection was dose dependent. "
01/01/2014 - "Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR."
09/01/2011 - "Ingenol Protects Human T Cells From HIV-1 Infection."
09/01/2011 - "Ingenol helps T cells to survive longer against viremia after HIV-1 infection, without exerting cytotoxic effects. "
09/01/2011 - "dUTP level related to late apoptotic events was increased on day 2 post-infection of HIV by ingenol treatment, whereas expression of annexin V was unchanged. "
|6.||Protein Kinase C
|9.||Diclofenac (SR 38)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Photochemotherapy (Photodynamic Therapy)